title: [Efficacy and safety of solifenacin in daily clinical practice--clinical study phase IV].
abstract: OBJECTIVE
  Symptoms of urinary urgency, frequency, nocturia with/or without urge incontinence, are reffered to as the overactive bladder (OAB). Main option for the treatment of the OAB are anticholinergic agents. The aim of the paper is to evaluate the efficacy and safety of the solifenacin in the daily clinical practice.
  
  
  METHODS
  344 patients with OAB symptoms (311 women, 33 men, average age 57.04 years) were enrolled into the study. Patients were treated with solifenacin 5 mg or solifenacin 10 mg in the flexible dosing regimen. Efficacy data were obtained from the validated questionnaries and micturion diaries. Safety assessment was based on adverse event reporting.
  
  
  RESULTS
  We observed a highly significant reduction of bladder problems caused by OAB (Patient Perception of Bladder Condition--PPBC/PBC score 4.83 at baseline to 3.29 at endpoint). The decrease of micturion frequency from baseline to endpoint was 31.19%, decrease of episodes of nocturia was 54.65 % and decrease of incontinence episodes was 90.19%. Average number of urgency episodes decresed from 12.46/day at baseline to 7.28/day at endpoint (41.6%). Average urgency severity decreased from 2.43 at baseline to 1.55 at endpoint (-37.4%). Adverse events were reported in 19 patients (5.52%) between visits 1 and 2 and in 16 patients (4.68%) between visits 2 and 3.
  
  
  CONCLUSIONS
  Results of our phase IV. study showed the excellent efficacy and safety profile of solifenacin in the treatment of OAB in accordance with results of published phase III. clinical studies.
authors.affiliation: Urologické oddelení FN Ostrava, Poruba jan.krhut@fnspo.cz
authors.forename: J
authors.initials: J
authors.lastname: Krhut
authors.forename: O
authors.initials: O
authors.lastname: Havránek
authors.forename: D
authors.initials: D
authors.lastname: Míka
authors.forename: M
authors.initials: M
authors.lastname: Fabisovský
authors.forename: P
authors.initials: P
authors.lastname: Valis
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D011812:Quinuclidines / Q000009:adverse effects / Q000627:therapeutic use*; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000009:adverse effects / Q000627:therapeutic use*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
chemical_list: D018727:Muscarinic Antagonists; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D000069464:Solifenacin Succinate